Concepedia

Tacrolimus in Corticosteroid-Refractory Vernal Keratoconjunctivitis

Samrat Chatterjee, Deepshikha Agrawal

Cornea · 2016 · 48 citations · 30 references

DOI

Abstract

Tacrolimus 0.03% was apparently safe and effective in treating patients with steroid-refractory VKC. A small subset of patients may still require supplemental topical corticosteroids for resolution of their symptoms.

References

30

Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP

Vassili Soumelis, Pedro A. Reche, Holger Kanzler et al. · Nature Immunology · 2002 · 2.1K citations

, , +13

Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation.

S Sawada, Gen Suzuki, Yoshiko Kawase et al. · The Journal of Immunology · 1987 · 417 citations · Full text

, , +16

Vernal keratoconjunctivitis revisited

Stefano Bonini, Alessandro Lambìase, S. Marchi et al. · Ophthalmology · 2000 · 413 citations

, , +3

Ocular complications of vernal keratoconjunctivitis.

Khalid F. Tabbara · PubMed · 1999 · 178 citations

A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis

Yuichi Ohashi, Nobuyuki Ebihara, Hiroshi Fujishima et al. · Journal of Ocular Pharmacology and Therapeutics · 2010 · 174 citations